Videos

Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on how BiTE therapy is changing care for relapsed/refractory multiple myeloma and how AON developed an all-outpatient step-up dosing model.

In addition to the upcoming Annual Forum in September, New England Institute of Ambulatory Care Pharmacists (NEIAP) provides practical education and networking opportunities to support ambulatory care pharmacists.

Wendy St Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and deprescribing.

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum and previews key topics of discussion.

The panelists examined the valuable role caregivers can play in identifying early TD movements, noting that patients often mask symptoms during office visits but may not do so around loved ones, and that caregiver education through accessible resources, such as sponsored videos, can help them recognize subtle signs

Tardive dyskinesia disrupts adherence, caregivers, and costs—learn why inpatient and telehealth visits often miss mild symptoms and what to do.

Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.

AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.

Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on why effective opioid stewardship in acute pain care must extend beyond prescription reduction to include multimodal analgesia, patient-centered outcomes, and standardized health-system pathways.

Yale's AZA Allsop, MD, PhD, on psychedelics as medicine vs wellness tools, and why naturalistic research settings matter for the field.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how multimodal, individualized care can improve acute pain management for opioid-tolerant patients and those receiving buprenorphine or methadone.

The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.

In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question: 1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?

Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.

Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discuss the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective VMAT2 inhibitor treatments have only been available since 2017.

Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?

Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.

A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.

Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.

Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.

GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.